BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36672148)

  • 1. Protein Kinase D3 (PKD3) Requires Hsp90 for Stability and Promotion of Prostate Cancer Cell Migration.
    Varga A; Nguyen MT; Pénzes K; Bátai B; Gyulavári P; Gurbi B; Murányi J; Csermely P; Csala M; Vántus T; Sőti C
    Cells; 2023 Jan; 12(2):. PubMed ID: 36672148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protein kinase D3 (PKD3) contributes to prostate cancer cell growth and survival through a PKCepsilon/PKD3 pathway downstream of Akt and ERK 1/2.
    Chen J; Deng F; Singh SV; Wang QJ
    Cancer Res; 2008 May; 68(10):3844-53. PubMed ID: 18483269
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PKD2 and PKD3 promote prostate cancer cell invasion by modulating NF-κB- and HDAC1-mediated expression and activation of uPA.
    Zou Z; Zeng F; Xu W; Wang C; Ke Z; Wang QJ; Deng F
    J Cell Sci; 2012 Oct; 125(Pt 20):4800-11. PubMed ID: 22797919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein Kinase D2 and D3 Promote Prostate Cancer Cell Bone Metastasis by Positively Regulating Runx2 in a MEK/ERK1/2-Dependent Manner.
    Roy A; Prasad S; Chen Y; Chao Y; Liu Y; Zhao J; Wang QJ
    Am J Pathol; 2023 May; 193(5):624-637. PubMed ID: 36740185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell surface heat shock protein 90 modulates prostate cancer cell adhesion and invasion through the integrin-β1/focal adhesion kinase/c-Src signaling pathway.
    Liu X; Yan Z; Huang L; Guo M; Zhang Z; Guo C
    Oncol Rep; 2011 May; 25(5):1343-51. PubMed ID: 21369706
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Protein kinase D3 is involved in negative regulation of MMP-7 in prostate cancer cells].
    Zou ZP; Feng L; Xu WF; Ke ZY; Wang QJ; Deng F
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Aug; 30(8):1767-70. PubMed ID: 20813660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression.
    He S; Zhang C; Shafi AA; Sequeira M; Acquaviva J; Friedland JC; Sang J; Smith DL; Weigel NL; Wada Y; Proia DA
    Int J Oncol; 2013 Jan; 42(1):35-43. PubMed ID: 23152004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [PKD3 contributes to up-regulation of prostate-specific antigen in prostate cancer cells].
    Deng F; Wang CX; Xu WF; Feng L; Ke ZY; Wang QJ; Zou ZP
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Aug; 30(8):1779-82. PubMed ID: 20813663
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and characterization of a novel C-terminal inhibitor of Hsp90 in androgen dependent and independent prostate cancer cells.
    Eskew JD; Sadikot T; Morales P; Duren A; Dunwiddie I; Swink M; Zhang X; Hembruff S; Donnelly A; Rajewski RA; Blagg BS; Manjarrez JR; Matts RL; Holzbeierlein JM; Vielhauer GA
    BMC Cancer; 2011 Oct; 11():468. PubMed ID: 22039910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of heat shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer.
    Lamoureux F; Thomas C; Yin MJ; Fazli L; Zoubeidi A; Gleave ME
    Eur Urol; 2014 Jul; 66(1):145-55. PubMed ID: 24411988
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inducible silencing of protein kinase D3 inhibits secretion of tumor-promoting factors in prostate cancer.
    LaValle CR; Zhang L; Xu S; Eiseman JL; Wang QJ
    Mol Cancer Ther; 2012 Jul; 11(7):1389-99. PubMed ID: 22532599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer cells.
    Gandhi N; Wild AT; Chettiar ST; Aziz K; Kato Y; Gajula RP; Williams RD; Cades JA; Annadanam A; Song D; Zhang Y; Hales RK; Herman JM; Armour E; DeWeese TL; Schaeffer EM; Tran PT
    Cancer Biol Ther; 2013 Apr; 14(4):347-56. PubMed ID: 23358469
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response.
    Armstrong HK; Koay YC; Irani S; Das R; Nassar ZD; ; Selth LA; Centenera MM; McAlpine SR; Butler LM
    Prostate; 2016 Dec; 76(16):1546-1559. PubMed ID: 27526951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytoprotective mitochondrial chaperone TRAP-1 as a novel molecular target in localized and metastatic prostate cancer.
    Leav I; Plescia J; Goel HL; Li J; Jiang Z; Cohen RJ; Languino LR; Altieri DC
    Am J Pathol; 2010 Jan; 176(1):393-401. PubMed ID: 19948822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824.
    Chen L; Meng S; Wang H; Bali P; Bai W; Li B; Atadja P; Bhalla KN; Wu J
    Mol Cancer Ther; 2005 Sep; 4(9):1311-9. PubMed ID: 16170022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 17-DMCHAG, a new geldanamycin derivative, inhibits prostate cancer cells through Hsp90 inhibition and survivin downregulation.
    Wang J; Li Z; Lin Z; Zhao B; Wang Y; Peng R; Wang M; Lu C; Shi G; Shen Y
    Cancer Lett; 2015 Jun; 362(1):83-96. PubMed ID: 25813406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interplay of PKD3 with SREBP1 Promotes Cell Growth via Upregulating Lipogenesis in Prostate Cancer Cells.
    Li L; Hua L; Fan H; He Y; Xu W; Zhang L; Yang J; Deng F; Zeng F
    J Cancer; 2019; 10(25):6395-6404. PubMed ID: 31772672
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The regulatory mechanism of a client kinase controlling its own release from Hsp90 chaperone machinery through phosphorylation.
    Lu XA; Wang X; Zhuo W; Jia L; Jiang Y; Fu Y; Luo Y
    Biochem J; 2014 Jan; 457(1):171-83. PubMed ID: 24117238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The heat shock protein 90 inhibitor, (-)-epigallocatechin gallate, has anticancer activity in a novel human prostate cancer progression model.
    Moses MA; Henry EC; Ricke WA; Gasiewicz TA
    Cancer Prev Res (Phila); 2015 Mar; 8(3):249-57. PubMed ID: 25604133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 17-Allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of prostate cancer xenografts.
    Solit DB; Zheng FF; Drobnjak M; Münster PN; Higgins B; Verbel D; Heller G; Tong W; Cordon-Cardo C; Agus DB; Scher HI; Rosen N
    Clin Cancer Res; 2002 May; 8(5):986-93. PubMed ID: 12006510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.